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Background: Repetitive Transcranial Magnetic Stimulation (rTMS) is an effective treatment for Major Depressive
Disorder (MDD), and is based upon delivery of focal high-energy pulses of electromagnetic stimulation. We
postulated that delivery of rTMS at the subject’s individual alpha frequency (synchronized TMS, or sTMS) would
achieve efficacy with lower energy of stimulation. We developed a device that rotates neodymium cylindrical
magnets at three locations along the midline above the subject’s scalp to impart low-energy, sinusoidal-waveform
magnetic brain stimulation over a broad area, and performed this efficacy study.
Method: Fifty-two subjects with MDD were enrolled in a randomized, sham controlled, double-blind treatment
study (Trial Registration: NCT01683019). Forty-six subjects were included in the final analysis. Most subjects received
concurrent antidepressant medications that remained unchanged during the study. Subjects were randomized to
three treatment groups: 1) active sTMS with a fixed frequency at the subject’s alpha frequency; 2) active sTMS with
a random stimulus frequency that varied between 8 Hz and 13 Hz; and, 3) sham sTMS. 20 half-hour sTMS sessions
were administered 5 days per week for 4 weeks.
Results: Subjects with either fixed or random frequency active sTMS had statistically significantly greater
percentage reduction in depression severity compared to sham (48.5% vs. 19.3%, respectively; p = 0.001). No
significant difference was found between fixed and random groups (p = 0.30). No significant side effects were
reported.
Conclusions: These results suggest that sTMS may be an effective treatment for MDD.
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Traditional repetitive Transcranial Magnetic Stimulation
(rTMS) directs high field strength magnetic pulses to a
single brain location, most commonly the dorsolateral
prefrontal cortex (DLPFC), as a treatment for Major De-
pressive Disorder (MDD) [1]. The study by O’Reardon
[2], and more recently in the OPT-TMS trial by George
[3], showed that this technique is an effective treatment
for MDD. In both studies, rTMS stimulation was admin-
istered at 120% of the motor threshold at a frequency of
10 Hz. The treatment paradigm was identical for all sub-
jects, regardless of their symptoms or characteristics of
brain function.* Correspondence: bill@neosync.com
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reproduction in any medium, provided the orThe mechanism of action of rTMS to achieve relief of de-
pressive symptoms remains incompletely understood. The
immediate effect of rTMS pulses on brain function is the
entrainment of cerebral oscillations to the frequency of
stimulation [4-9]. Evidence suggests that rTMS may achieve
therapeutic effectiveness through resetting of thalamocorti-
cal oscillators [10]. Repetitive entrainment of endogenous
oscillations to a 10 Hz frequency of stimulation may facili-
tate the reemergence of intrinsic cerebral rhythms, thereby
restoring normal brain function. Questions remain, how-
ever, as to the optimal stimulation parameters to achieve
this resetting of oscillators. Stimulation variables that have
not been systematically studied include stimulus intensity,
frequency, and location. We hypothesized that it may be
possible to improve the effectiveness of rTMS treatmentral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pulses to the frequency of the patient’s individual alpha fre-
quency (IAF), called synchronous TMS (sTMS) [10]. By
synchronizing TMS to the IAF, it may be possible to use a
low magnetic field strength sinusoidal waveform applied
broadly across the brain, in contrast to the focal high
strength magnetic field pulses traditionally utilized.
We report here on the first pilot trial of an experi-
mental device designed to administer low-energy sinus-
oidal waveform sTMS to patients suffering from MDD.
This device uses three neodymium permanent magnets
that rotate at a programmed frequency or set of fre-
quencies at or near the subject’s IAF, thereby imparting
low energy stimulation broadly over the brain to en-
train brain oscillations and potentially reset thalamo-
cortical oscillators. This pilot study was designed to
examine the feasibility of the technique, and an initial
methodological validation of the possible efficacy of this
new treatment modality.Figure 1 Location of the three cylindrical magnets above the
subject’s head.Methods
The aim of the clinical trial was to determine the effi-
cacy of the sTMS treatment in comparison to sham, and
to examine issues of safety related to the investigational
device.Figure 2 Subject lying under the magnet housing of the sTMS
device undergoing treatment.Experimental device
The sTMS device employs cylindrical neodymium mag-
nets that are diametrically magnetized, with a surface
field of 6,430 Gauss (0.64 T). The three magnets are po-
sitioned sagitally along the midline with the axis of rota-
tion perpendicular to the midline (See Figure 1). Magnet
#1 is located just above the eyebrows, closest to the front
polar region of the brain. Magnet #2 is on the top of the
head, 7 cm behind Magnet #1 approximately overlying
the superior frontal gyrus. Magnet #3 is 9 cm behind
Magnet #2 approximately overlying parietal region of
the cortex. The magnets are positioned to provide a glo-
bal magnetic field distributed broadly across the midline
cortical surface.
The primary differences between the sTMS device
used in the study and a standard rTMS system, other
than the delivery mechanism are the magnetic field
waveform (i.e., sinusoidal vs pulsed) and the intensity of
stimulation. The maximum change in magnetic field
over time (max dB/dt) for the sinusoidal waveform is
227 Gauss/msec, whereas the max for rTMS is approxi-
mately 185 kGauss/msec. Because the electric potential
induced by a magnetic field is proportional to dB/dt, the
energy of the sinusoidal magnetic field is estimated at
less than 1% that of a standard rTMS system. Therefore,
sTMS stimulation is sub-threshold and does not directly
cause neuronal depolarization, but instead uses a low-level alternating induced electric field to entrain neur-
onal firing at the programmed frequency.
The device uses a mechanical closed-loop control sys-
tem to rotate magnets secured inside an assembly. The
magnet assembly is lowered and secured in place on the
subject’s scalp. The subject lays face up under the device
with eyes closed while the magnets rotated above the
subject’s head (Figure 2).
To create a sham for a double-blinded trial, we con-
structed the sTMS device in the same way, except that
it rotated non-magnetized steel cylinders instead of
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the active device, except that no alternating magnetic
field was generated. The sham was indistinguishable
from the active device in that it looked identical, and
had a similar sound and vibration when in operation.
Procedures and subjects
Trial summary
This double-blinded, randomized, three-arm clinical trial
was conducted at two sites in Newport Beach, California
and Beijing, China. A total of 52 subjects with MDD were
enrolled. All subjects were diagnosed by a physician as
having moderate to severe MDD using DSM IV criteria
based upon a structured clinical interview, with severity as
defined by a Hamilton Depression Rating Scale (HAMD-
17) [11] greater than or equal to a score of 17. Study sub-
jects were treated five days per week for four weeks, with
treatment consisting of a single 30-minute session. All
treatment sessions were administered at the study site.
Subjects were evaluated weekly throughout the trial to
track progress and monitor any safety issues. All study
subjects were allowed to use concomitant antidepressant
treatment but were required to be stable on the medica-
tion for greater than one month prior to the start of the
study. No adjustment of antidepressant medication was
allowed during the study. The determination of clinical
outcome was based on change in HAMD-17 score at the
end of 4 weeks of treatment.
Ethical approval
All experimental procedures were conducted with the
approval of the appropriate IRB (Alpha IRB, San Clem-
ente, CA and Peking University Hospital IRB, Beijing,
China). The study was conducted with the understand-
ing and written consent of each participant both in the
US and China. The study was registered with clinical-
trials.gov (NCT01683019).
Inclusion and exclusion criteria
Inclusion criteria
Subjects could be included only if they satisfied the fol-
lowing inclusion criteria: (1) 18 years of age or older; (2)
diagnosis of MDD with HAM-D 17 ≥ 17; and (3) on a
stable dose of the existing medication or no medication
for 1 month or longer prior to the study.
Exclusion criteria
Subjects were excluded from study participation if any of
the following exclusion criteria applied: (1) Diagnosed
with another primary Axis I illness; (2) recent history of or
current substance abuse; (3) clinically significant medical
illness, including any thyroid disorders; or (4) known preg-
nancy and/or lactation, or intent to become pregnant dur-
ing the study.Randomization
Each subject’s EEG was recorded after randomization to
determine his or her IAF. EEGs were recorded using a
Cadwell Easy II unit, and the IAF was found using a pro-
prietary algorithm designed to detect the frequency in
the alpha range (8.0 – 13.0 Hz) with maximum energy,
confirmed through visual inspection of the EEG signal.
Study subjects were randomized to one of three treat-
ment arms with equal probability. The randomization
table was created using a random number generator
treating the all subjects as a single group. No blocking
or stratification was used. The treatment arms were:
 Fixed frequency magnet rotation, set to the subject’s
average IAF ± 0.1 Hz.
 Random frequency magnet rotation, which hopped
to random frequencies between 8.0-13.0 Hz once
per second, with a resolution to 0.1 Hz.
 Sham. Treatments appeared and sounded similar to
active treatment except that no magnetic field was
generated.
Outcomes and data analyses
The primary objective of the study was to establish the
efficacy of sTMS in comparison to a sham treatment
in subjects with moderate to severe MDD. The treat-
ment outcomes were analyzed for the intent-to-treat
sample with the primary outcome being the percent re-
duction from baseline to endpoint on the HAMD-17
rating scale, using the last observation carried forward
(LOCF) method for interpolating final score for those
subjects who discontinued before the final endpoint.
Non-parametric analysis was used to compare grouping
differences as measured by the number of responders
(defined as > 50% reduction from baseline to final end-
point) and remitters (defined as a final HAMD-17 ≤ 7).
Analysis of Variance with repeated measure of time
followed by post-hoc t-tests as indicated for each time
point was performed to determine if there was as differ-
ence in outcome among the three groups based on per-
cent reduction in symptom severity. The secondary
objective was to describe the safety profile of the device
in a clinical setting.
Results and discussion
As shown in Table 1, no clinically relevant differences
between the two sites were observed at baseline for
demographic characteristics or baseline MDD severity.
Table 2 lists all concomitant medications used by sub-
jects in the study; there was no significant difference in
the number or type of medications among subjects in
the various response or treatment groups. The medica-
tions were not thought to affect the subjects’ alpha fre-
quency, and therefore are not considered a factor.
Table 1 Clinical study demographic and baseline clinical information
Active sTMS SHAM Statistics
Gender (Male: Female) 13:16 7:9 X2 = 0.11, p = 0.74
Age (s.d.) 42.5 (15.0) 46.3 (12.7) t = 0.85, p = 0.40
Years of education (s.d.) 13.9 (4.2) 14.1 (3.2) t = 0.16, p = 0.87
Duration of illness in months (s.d.) 11.1 (9.7) 13.6 (11.4) t = 0.79, p = 0.44
Hamilton score (s.d.) 21.3 (4.0) 19.4 (4.1) t = 1.55, p = 0.13
Antidepressants (SSRI / other) 28 /3 15 /0 X2 = 1.55, p = 0.21
Alpha EEG frequency (s.d.) 9.7 (0.9) 9.3 (1.1) t = 1.39, p = 0.17
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withdrew in the first week due to problems with trans-
portation to the study sites and one subject withdrew
during Week 3. Data were analyzed using all subjects
who completed at least one efficacy assessment (46 in
total), with the last available HAMD-17 value carried
forward for Week 4 outcome analysis (LOCF method).
No study site by treatment interaction was found
(F1,44 = 0.22, p = 0.64), so that data were pooled across
study sites. The HAMD-17 score mean and standard de-
viation at baseline and at the end of each week of treat-
ment were determined, as shown in Table 3. For both
active groups, no significant treatment difference be-
tween fixed frequency and random frequency was found
(F1,28 = 1.09, p = 0.30). Therefore, the fixed and random
frequency groups are combined into a single active
group for this analysis.
The average percentage improvement in HAMD-17
score was determined for the active and sham groups, as
shown in Figure 3. The active group was significantly
better than the sham as an overall measure (F1,44 =
10.70, p = 0.002), and on a time-by-treatment interaction
(Greenhouse-Geisser adjustment F1.9,85.1 = 4.1, p = 0.02).
There were significantly more responders in the activeTable 2 List of concomitant medication used by subjects
in the study, with the number of subjects using the
medication
Alprazolam (4) Esomeprazole (1) Oxycodone (1)
Amitriptyline (3) Fluoxetine (10) Paroxetine (4)
Budesonide (1) Flupentixol (4) Pentosan Polysulfate (1)
Bupropion (3) Fluvoxamine (1) Sertraline (3)
Busparinone (1) Gabapentin (1) Sucralfate (1)
Cetirizine (1) Lorazepam (5) Sumatriptan (1)
chlorpromazine (1) Maprotiline (1) Tolterodine (1)
Citalopram (3) Mentropolol (1) Topiramate (1)
Clonazepam (6) Metaxalone (1) Venlafaxine (4)
Duloxetine (1) Montelukast (1)
Escitalopram (3) Olazapine (1)
Note, some subjects were on more than one medication.treatment group (16/30 or 53.3%) compared to sham
(2/16 or 12.5%) (χ2 = 7.30, p = 0.007). In the active group,
12/30 (37.9%) reached remission (HAMD-17 ≤ 7, six in
the fixed frequency group and five in the random fre-
quency group). Only one sham patient (6.25%) remitted
(p = 0.015).
There was no significant change in IAF value during
the 4 weeks of treatment. No subject reported a sensa-
tion during treatment other than feeling a slight vibra-
tion where the treatment arm made contact with the
head. Approximately 50% of subjects (both sham and ac-
tive groups) reported an occasional mild headache that
went away shortly after treatment. This was likely due to
vibrations of the prototype. A mild, light-headed feeling
was reported by approximately 40% of subjects in the ac-
tive group, either immediately or up to two hours after
treatment. No sham subject reported light-headedness.
Conclusions
In this study, a statistically significant decrease in
HAMD-17 score was observed in subjects treated with
the sTMS device compared to sham. These results indi-
cate that a sub-threshold alternating sinusoidal magnetic
field generated in the alpha frequency range can have
therapeutic efficacy in patients with MDD. The sub-
threshold alternating electrical field in the brain gener-
ated by the sTMS device would not actively depolarize
neurons, but instead may influence neurons to fire at
the induced frequency by modulating the threshold po-
tential required for depolarization. These results support
the hypothesis that a sinusoidal magnetic field applied at
or near the IAF has a significant effect on brain function,
possibly through entrainment of oscillations to theTable 3 Weekly HAMD-17 scores for the three groups
SHAM Fix Random
Baseline (s.d.) 20.0 (4.6) 21.4 (3.9) 20.8 (3.7)
Week 1 (s.d) 18.6 (5.4) 19.4 (3.6) 16.4 (7.1)
Week 2 (s.d) 17.8 (6.0) 17.0 (4.0) 14.6 (4.9)
Week 3 (s.d) 16.0 (5.3) 13.3 (5.1) 12.4 (4.4)
Week 4 (s.d) 15.9 (5.9) 11.7 (5.9) 10.1 (4.7)
Figure 3 Average improvement in HAMD-17 score for the active group compared to sham (** shows p < 0.01).
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oscillators, promote synaptic plasticity, and change brain
function and patients’ mood through a mechanism simi-
lar to conventional rTMS systems [10].
The results of this study need to be interpreted within
the context of several limitations. In the present study,
clinical improvement was seen during the 4 weeks of
treatment. It is not clear, however, that this is necessarily
the optimal length of treatment. Subjects were contacted
informally by telephone 4 weeks after the completion of
the study to ensure there were no latent adverse effects,
but no long-term clinical data was obtained. We would
anticipate future studies to evaluate possible long-term
effects of sTMS.
Our study found that the subjects treated at the IAF
showed improvement that was numerically, but not sta-
tistically significantly greater, than subjects treated at an
active random-frequency in the alpha range. These data
suggest that there may be an advantage to matching the
IAF, but neither prove nor disprove the hypothesis. One
reason for this finding may be that the bandwidth of in-
fluence is large enough that any frequency in the alpha
band may have an effect. This may also be a contributing
factor to the efficacy of standard rTMS, which delivers
treatment at a fixed 10 Hz, in the center of the alpha
band. In a future clinical trial, it would be beneficial to
compare the results of matching the IAF to an active de-
vice set to a more remote frequency, such as one in the
beta or theta band.
The sTMS device used in this study was designed pri-
marily to deliver stimulation at a specific frequency or
set of frequencies. Other design decisions were made
on a practical basis to make it feasible to build a first-
generation sTMS device that could operate reliably in a
multi-site clinical trial. Three rotating magnets were
chosen to deliver treatment broadly over the midlineregion; it is possible that a different number of magnets
in the same or different locations might match or
exceed the efficacy seen in this study. As is evident in
Figure 1, the rotating magnets are 180 degrees out of
phase with each other. This creates the same phase re-
lationship in the electric field generated in the brain.
The relationship between the magnets was not chosen
due to any perceived benefit of opposite phases. In-
stead, this relationship between magnets allowed for a
smaller motor required to turn the magnets. Additional
research into the benefits of different phase relation-
ships would be valuable.
This study aimed to examine only the safety and effi-
cacy of sTMS treatment. Future studies should also
examine the effects of sTMS on various biological met-
rics, such as alpha power, frequency selectivity, blood
flow, or EEG coherence. In the present study, both ac-
tive groups (fixed and random frequency) had a positive
effect on symptoms. Future studies should go further
to establish clearly which technique achieves the most
significant response. The present findings suggest that
the sTMS device can be an efficacious treatment for
MDD, and supports the conduct of a larger, definitive
clinical trial.Abbreviations
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